Researchers combined a phenotypic screen of around 1,200 approved drugs with Boltz-2 structural modeling to identify inhibitors of NALCN, a sodium leak channel mutated in the ultra-rare neurodevelopmental condition CLIFAHDD.
Nattaya Thongsepee, Jeremy A Tanner, Srikanth Polusani, and 8 othersNattaya Thongsepee, Jeremy A Tanner, Srikanth Polusani, Alexandra Typou, Nicholas A. Clanton, Brandon B. Holmes, Philippe Lory, Donard S. Dwyer, Daohong Zhou, Arnaud Monteil, Yaxia Yuan fewer authors
Thammasat University; University of Texas; INSERM; and 3 othersThammasat University; University of Texas; INSERM; CNRS; University of California, San Francisco; LSU Health Shreveport fewer institutions